SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-090024
Filing Date
2023-08-11
Accepted
2023-08-11 06:15:30
Documents
7
Period of Report
2023-09-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2322443-2_def14a.htm DEF 14A 624417
2 GRAPHIC bc_incomevscompactpaid-4c.jpg GRAPHIC 101435
3 GRAPHIC bc_tsrvscompactpaid-4c.jpg GRAPHIC 101776
4 GRAPHIC lg_neubase-bw.jpg GRAPHIC 19998
5 GRAPHIC px_neuproxy01pg01-bw.jpg GRAPHIC 761907
6 GRAPHIC px_neuproxy01pg02-bw.jpg GRAPHIC 480835
7 GRAPHIC sg_dietrichstephan-bw.jpg GRAPHIC 20132
  Complete submission text file 0001104659-23-090024.txt   2383200
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

IRS No.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35963 | Film No.: 231161414
SIC: 2834 Pharmaceutical Preparations